The consolidated results for the second quarter of the fiscal year ending December 2026 show continued losses. Revenue is 645,423 thousand USD (interim), operating loss is \u25b35,376,995 thousand USD, net loss attributable to parent company shareholders for the interim is \u25b34,900,397 thousand USD. The full-year guidance for the fiscal year ending December 2026 has not been disclosed at this time. Yorkville SEPA and Lucid sale agreements are retained; cash is 25.4 million USD, working capital is 23.0 million USD. Key financials include current assets about 25.9 million USD, shareholders\u2019 equity about 37.3 million USD.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4875","jir_company_name":"Medicinova, Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-14","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4875-20260814-01.pdf","jir_short_summary":"The consolidated results for the second quarter of the fiscal year ending December 2026 show continued losses. Revenue is 645,423 thousand USD (interim), operating loss is \u25b35,376,995 thousand USD, net loss attributable to parent company shareholders for the interim is \u25b34,900,397 thousand USD. The full-year guidance for the fiscal year ending December 2026 has not been disclosed at this time. Yorkville SEPA and Lucid sale agreements are retained; cash is 25.4 million USD, working capital is 23.0 million USD. Key financials include current assets about 25.9 million USD, shareholders\u2019 equity about 37.3 million USD.","jir_summary":"### Summary of Results\nThis earnings report discloses the interim period results under U.S. GAAP: revenue of 645,423 thousand USD, operating loss of \u25b35,376,995 thousand USD, and interim net loss of \u25b34,900,397 thousand USD. No full-year guidance has been published at this time. Cash and cash equivalents amount to 25,415,921 thousand USD, and shareholders\u2019 equity stands at 37,270,602 thousand USD. Financing arrangements via Yorkville SEPA provide up to 30.0 million USD, and a stock sale agreement via Lucid remains up to 50.0 million USD.\n\n### Capital Policy and Financing Trends\nDuring the interim period, the Company retains the right to periodically dispose of shares via Yorkville. Structuring fees and commitment fees payable to Yorkville have been paid. The stock sale agreement via Lucid has not been executed at this time. Attention to cash generation stability is required, and working capital is expected to be secured through November 2027, though this does not guarantee full funding of all programs.","jir_financial_highlights":"Revenue: 645,423 (Interim period vs previous interim: \u25b3103,732)\nOperating loss: -5,376,995 (YoY)\nInterim net loss: -4,900,397 (YoY comparison unavailable)\nCash and cash equivalents: 25,415,921 (decrease from prior period)\nShareholders' equity: 37,270,602 (decrease vs prior year-end)","jir_category":"","jir_hashtags":"#MedicinovaInc, #Earnings, #InterimEarnings, #FinancialPosition","jir_key_figures":"Revenue: 645,423\nInterim net loss: \u25b34,900,397\nCash and cash equivalents: 25,415,921","jir_meta_title":"Medicinova, Inc. | Fiscal Year Ending December 2026 Q2 Interim Financial Results Report | U.S. GAAP","jir_meta_description":"Summary of Medicinova, Inc.'s Q2 2026 interim earnings. Covers revenue, profit or loss, financial position, cash and working capital, and capital policy developments including SEPA with Yorkville and Lucid agreements.","jir_og_title":"Medicinova, Inc. | Fiscal Year Ending December 2026 Q2 Interim Financial Results Report","jir_og_description":"Medicinova, Inc.'s interim earnings show ongoing losses. Revenue is 645,423 thousand USD, interim net loss is \u25b34,900,397 thousand USD. Cash stands at 25,415,921 thousand USD, with developments on Yorkville SEPA and Lucid agreements summarized.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58821,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-103751","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n